Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

BACKGROUND: In the phase 3 RADIANT-2 study, everolimus plus octreotide long-acting repeatable (LAR) showed improvement of 5.1 months in median progression-free survival versus placebo plus octreotide LAR among patients with advanced neuroendocrine tumors associated with carcinoid syndrome. The progr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Pavel, M.E., Baudin, E., Öberg, K.E., Hainsworth, J.D., Voi, M., Rouyrre, N., Peeters, M., Gross, D.J., Yao, J.C.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Gastrointestinal tumor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360141/
https://ncbi.nlm.nih.gov/pubmed/28444114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx193
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados